摘要
目的提示临床注射用美罗培南联合注射用盐酸万古霉素使用过程中需加以关注可能引起的粒系骨髓抑制不良反应。方法报道1例脑出血术后患者治疗期间发生严重粒系骨髓抑制,通过不良反应相关性分析鉴别该患者粒系骨髓抑制不良反应发生的可能药物。结果患者不良反应严重程度为骨髓抑制程度Ⅳ级,排除患者病情和合并用药情况,判断引起患者严重骨髓抑制的药物为联用的抗菌药物注射用美罗培南和注射用盐酸万古霉素,不良反应相关性评价为“很可能”,立即予以停药并对症处理后患者好转。结论联合使用的注射用美罗培南和注射用盐酸万古霉素引起的Ⅳ级骨髓抑制不良反应报道少见,临床药物治疗过程中应加以识别。
Objective To remind clinicians of possible adverse reactions of granulocytic myelosuppression induced by meropenem and vancomycin injections in clinical use.Methods One case of severe granulocytic myelosuppression was reported in a patient after cerebral hemorrhage surgery.Correlation analysis of the adverse reactions was conducted to identify the possible drug responsible for the occurrence of granulocytic myelosuppression in the patient.Results The severity of the adverse reactions was grade IV myelosuppression.The patient’s condition and concomitant medication were excluded before the cause of severe myelosuppression was determined to be the combined use of antibacterial meropenem and vancomycin injections.The relevance of adverse reactions was evaluated as“probable”.The drug was immediately discontinued and the patient was improved after symptomatic treatment.Conclusion Adverse reactions of grade IV myelosuppression induced by the combined use of antibacterial meropenem and vancomycin injections are rarely reported and should be identified during clinical drug treatment.
作者
刘保华
沈爱宗
苏丹
LIU Baohua;SHEN Aizong;SU Dan(Department of Pharmacy,Ma’anshan Hospital of Traditional Chinese Medicine,Ma’anshan Anhui 243000,China;Department of Pharmacy,University of Science and Technology of China First Hospital,Hefei Anhui 230000,China)
出处
《中国药物警戒》
2023年第3期339-342,共4页
Chinese Journal of Pharmacovigilance
基金
国家科技重大专项重大新药创制(2020ZX09201-004)
安徽省重点研究与开发计划(202004j07020023)
2018国家卫计委药政司委托研究课题-各级医疗机构用药目录共同性研究(药政[2018]购2号)
安徽省卫生健康软科学研究项目(2020WR0301)。
